FocalTherics (NASDAQ:FOCL) SVP Purchases 5,000 Shares of Stock

Key Points

• Insider buying: SVP Steven Annen purchased 5,000 FocalTherics shares at an average price of $4.75, investing $23,750 and increasing his ownership by 3.8% to 136,490 shares.
• Weak quarterly results: FocalTherics reported a quarterly loss of $0.39 per share, missing the $0.20 consensus estimate, on revenue of $13.2 million. The company posted a negative net margin of 56.26%.
• Mixed analyst outlook: Ratings range from Strong Buy to Sell, resulting in a consensus “Hold” rating and a $7.75 price target, compared with the stock’s recent price near $4.76.

FocalTherics (NASDAQ:FOCL - Get Free Report) SVP Steven Annen acquired 5,000 shares of the business's stock in a transaction that occurred on Friday, August 14th. The shares were bought at an average price of $4.75 per share, for a total transaction of $23,750.00. Following the completion of the purchase, the senior vice president owned 136,490 shares of the company's stock, valued at approximately $648,327.50. This represents a 3.80% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

FocalTherics Price Performance

FOCL stock opened at $4.76 on Monday. The firm has a market capitalization of $178.40 million, a P/E ratio of -4.62 and a beta of -0.04. The business has a 50-day moving average of $5.39. FocalTherics has a fifty-two week low of $1.30 and a fifty-two week high of $6.40. The company has a quick ratio of 0.99, a current ratio of 1.34 and a debt-to-equity ratio of 1.79.

FocalTherics (NASDAQ:FOCL - Get Free Report) last released its earnings results on Friday, August 14th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.19). The company had revenue of $13.20 million for the quarter. FocalTherics had a negative net margin of 56.26% and a negative return on equity of 175.45%. Equities analysts anticipate that FocalTherics will post -0.78 EPS for the current year.

Institutional Investors Weigh In On FocalTherics

Institutional investors and hedge funds have recently modified their holdings of the stock. Flax Pond Capital LLC bought a new stake in shares of FocalTherics during the 4th quarter worth $2,623,000. Leonteq Securities AG acquired a new stake in shares of FocalTherics during the fourth quarter worth $313,000. Rock Springs Capital Management LP lifted its holdings in shares of FocalTherics by 7.1% during the first quarter. Rock Springs Capital Management LP now owns 1,378,000 shares of the company's stock valued at $5,126,000 after purchasing an additional 91,500 shares during the last quarter. Kovack Advisors Inc. purchased a new stake in shares of FocalTherics during the fourth quarter valued at $53,000. Finally, Lido Advisors LLC acquired a new position in shares of FocalTherics in the 1st quarter valued at $40,000. Institutional investors and hedge funds own 62.74% of the company's stock.

Analysts Set New Price Targets

Several brokerages have recently weighed in on FOCL. Piper Sandler restated a "neutral" rating and issued a $4.00 price objective on shares of FocalTherics in a report on Friday. Wall Street Zen cut shares of FocalTherics from a "hold" rating to a "sell" rating in a research report on Saturday. Mizuho set a $15.00 price target on shares of FocalTherics and gave the company an "outperform" rating in a report on Friday, July 17th. Finally, HC Wainwright restated a "buy" rating and set a $10.00 price objective on shares of FocalTherics in a research report on Tuesday, June 2nd. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $7.75.

FocalTherics Company Profile

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source